Verona Pharma plc Verona Pharma To Announce Interim Results For The Three And Nine Months Ended September 30, 2020 And Provid...

 
TIDMVRP 
 
   LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona 
Pharma plc (AIM: VRP) (Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage 
biopharmaceutical company focused on respiratory diseases, announces 
that it will report its unaudited financial results for the three and 
nine months ended September 30, 2020 on Thursday, October 29, 2020 and 
host an investment community conference call at 9:00 a.m. EDT / 1:00 
p.m. GMT to discuss these financial results and provide a corporate 
update. 
 
   To participate, please dial one of the following numbers and reference 
conference ID 2469127: 
 
 
   -- [phone] for callers in the United States 
 
   -- [phone] for international callers 
 
 
   A live webcast will be available on the Events and Presentations link on 
the Investors page of the Company's website, www.veronapharma.com, and 
an audio replay will be available there for 90 days. 
 
   For further information, please contact: 
 
 
 
 
 
  Verona Pharma plc                                       Tel: [phone] 
------------------------------------------------------  --------------------------- 
  Victoria Stewart, Director of Communications            [e-mail] 
------------------------------------------------------  --------------------------- 
 
  N+1 Singer                                              Tel: [phone] 
   (Nominated Adviser and UK Broker) 
------------------------------------------------------  --------------------------- 
  Aubrey Powell / George Tzimas / Iqra Amin (Corporate 
   Finance) 
------------------------------------------------------  --------------------------- 
  Tom Salvesen (Corporate Broking) 
------------------------------------------------------  --------------------------- 
 
  Optimum Strategic Communications                        Tel: [phone] 
   (European Media and Investor Enquiries)                 [e-mail] 
------------------------------------------------------  --------------------------- 
  Mary Clark / Eva Haas / Shabnam Bashir 
------------------------------------------------------  --------------------------- 
 
  Argot Partners                                          Tel: [phone] 
   (U.S. Investor Enquiries)                               [e-mail] 
------------------------------------------------------  --------------------------- 
  Kimberly Minarovich / Michael Barron 
------------------------------------------------------  --------------------------- 
 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. If 
successfully developed and approved, Verona Pharma's product candidate, 
ensifentrine, has the potential to be the first therapy for the 
treatment of respiratory diseases that combines bronchodilator and 
anti-inflammatory activities in one compound. The Company is evaluating 
nebulized ensifentrine in its Phase 3 clinical program ENHANCE 
("Ensifentrine as a Novel inHAled Nebulized COPD thErapy") for COPD 
maintenance treatment. The Company raised gross proceeds of $200 million 
through a private placement in July 2020 and expects the funds to 
support its operations and Phase 3 clinical program into 2023. Two 
additional formulations of ensifentrine are currently in Phase 2 
development for the treatment of COPD: dry powder inhaler ("DPI") and 
pressurized metered-dose inhaler ("pMDI"). Ensifentrine is in a pilot 
clinical study in patients hospitalized with COVID-19 and has potential 
applications in cystic fibrosis, asthma and other respiratory diseases. 
For more information, please visit www.veronapharma.com. 
 
 
 
 

(END) Dow Jones Newswires

October 22, 2020 02:00 ET (06:00 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.